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Summary
Indomethacin and alclofenac were compared for 13
months under double-blind conditions in 109 patients
with active, classical, or definite rheumatoid arthritis
at a relatively early stage of the disease. Both indo-
methacin and alclofenac were clearly effective: most
patients either improved or remained as well controlled
as on entry. Alclofenac proved the more effective drug,
however, producing a significantly greater reduction in
morning stiffness, articular index, and erythrocyte
sedimentation rate, and only in the alclofenac-treated
group did functional capacity improve and latex-
agglutination titres diminish. Comprehensive laboratory
tests showed no significant deviation from normal
which could have been attributed to either drug.
Introduction
In the treatment of rheumatoid arthritis one or more non-
hormonal anti-inflammatory drugs will probably be adminis-
tered for several months or years, yet the few long-term con-
trolled, double-blind assessments of such drugs show that
neither non-hormonal, anti-inflammatory agents nor corti-
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costeroids suppress inflammation sufficiently to prevent joint
disease and crippling deformities (Medical Research Council
and Nuffield Foundation Joint Committee, 1959, 1960).
Though it seems that these drugs have little more than a brief
effect on disease activity in rheumatoid arthritis they certainly
provide the mainstay of current antirheumatic drug therapy,
but even for this limited objective there are relatively few
effective drugs and none devoid of toxicity. Duthie (1971) has
argued that the modest anti-inflammatory activity possessed by
current antirheumatic drugs is a factor in their favour since
rheumatoid arthritis, though painful and disabling, is relatively
non-lethal and functional activity can be maintained for many
years (Duthie et al., 1964). The various antiproliferative drugs
which have produced a modest but discernible improvement
in patients with rheumatoid arthritis (Mason et al., 1969;
Plotz, 1972; Steinburg, 1973; Currey et al., 1974) have yet to
be evaluated for the hazards of oncogenesis, mutagenesis, and
long-term toxicity which might accompany their use in patients
with relatively early disease. Reports of adverse effects on gona-
dal function in both sexes during the administration of anti-
proliferative drugs (Fairley et al., 1972; Kumar et al., 1972),
however, raise serious doubts about their potential therapeutic
efficacy in rheumatoid arthritis.
To evaluate the effects of non-steroidal antirheumatic drugs
in the extended treatment of patients with rheumatoid arthritis
at a relatively early stage of the disease we compared a fairly
new non-steroidal antirheumatic drug, alclofenac, with an
established drug, indomethacin, in a controlled, double-blind,
between-patient trial over 13 months.
Methods
Patients.-All the patients admitted to the study had "definite" or
"classical" rheumatoid arthritis (American Rheumatism Association
(A.R.A.) criteria) and laboratory and clinical evidence of active
disease for at least one year. They were all positive for rheumatoid
factor (latex test 1/80) with radiological evidence of joint erosions.
Patients were excluded ifthey had received gold therapy, penicillamine,
or antimalarial drugs during the 18 months before the trial. Patients
were also excluded if they had suffered from persistent dyspepsia
or were at risk of becoming pregnant. Those taking corticosteroids
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were admitted only when the dose had been stable for the preceding
four months.
Drugs.-Two treatments were compared: indomethacin 150-
200 mg daily, and alclofenac 3-4 g daily. Each drug was given in
identical capsules in divided doses of six to eight capsules a day.
Patients were randomly allocated to each treatment but were stratified
according to sex, duration of disease, and whether or not they were
receiving corticosteroids. Initially, each patient received six capsules
daily, which was increased to a maximum of eight capsules if necessary
to obtain satisfactory treatment. Only paracetamol or dextropropoxy-
phene was allowed as a supplementary analgesic, and the consumption
was recorded. Unused trial capsules and analgesic tablets were re-
turned for counting at every visit.
Clinical Assessment.-At each visit the following assessments were
made: overall joint pains (graded as severe, moderate, mild, or none);
pain on palpating the joints, using the articular index of Ritchie
et al. (1968); the duration of early morning stiffness; functional capa-
city (Steinbrocker et al., 1949); grip strength (sphygmomanometer
cuff compression); digital joint size (Boardman and Hart, 1967); and
walking time over 15 metres. To assess changes in the patients' con-
ditions during the course of the study they were grouped into 10
severity classes (A-J) at each visit according to the criteria of the
American Rheumatism Association Co-operating Clinics Committee
(1967). Allocation to a class was based on the patients' scores on grip
strength, morning stiffness, functional capacity, and articular index.
Laboratory Investigations.-A full blood count, erythrocyte sedi-
mentation rate (E.S.R.), blood urea, and serum enzymes (SGOT,
SGPT, and lactate dehydrogenase) were recorded fortnightly for the
first two months and monthly thereafter. At the same intervals stan-
dard liver function tests and urinalysis for protein, glucose, and blood
were performed. Latex agglutination tests, and x-ray examination of
hands and feet were carried out every three months.
Procedure.-After a two-week "baseline" observation period
patients were assessed every four weeks. Treatment was discontinued
if the patients failed to manage on the maximum daily dosage of the
trial drug or developed persistent dyspepsia, proteinuria, pruritus,
rash, or any other adverse effects which might have been caused by
the drugs being tested.
Results
A total of 109 patients were admitted to the trial. Fifty-eight received
indomethacin and 51 alclofenac. There were similar numbers of
patients receiving corticosteroids in each group (eight and seven).
Eighty patients completed 56 weeks of the trial, and 20 of the remain-
ing 29 were withdrawn because of what were considered to be adverse
reactions to a trial drug. Comparability of the two treatment groups
on admission indicated that none of the differences were significant
at the 10% (table I). The duration of disease was less than three years
in 48% of all patients and less than five years in 62%.
TABLE i-Comparability of Indomethacin-treated and Alclofenac-treated
Patients with Rheumatoid Arthritis at Initial Assessment. Values are Means
S.D.
Indomethacin Alclofenac
No. of patients .. .. 58 51
Age (years) . .52 ± 8-0 51 + 90
Sex.29M. 29 F. 25 M. 26 F.
Duration of disease (years) 5-2 ± 2-9 5-8 ± 2-5
Functional capacity score 2-0 ± 0-86 19 ± 0-83
Overall joint pain score.. 2-72 ± 075 2-74 ± 0-77
Articular index score .51-0 27-3 53-6 24-5
Grip strength (mm Hg)t .. 191 21 193 18
Duration of morning stiffness (min) 229 59 231 + 6-1
Walking time over 15 m (sec) 66 49-1 73 38-9
Digital joint size (mm) .499 27 502 25
tGrip strength values are total of values for each hand.
Double-blind conditions were adequately maintained, and the
treatment was consistently guessed correctly by the clinician in only
three cases (indomethacin in each case).
Both groups of patients tended to reduce their supplementary
analgesic intake during the first six weeks of the trial and to increase it
during the third and fourth months. During these periods there were
no significant differences in analgesic requirements between the groups.
From the fifth to the 13th month of the trial, however, both groups
again tended to reduce their analgesic supplements, the reduction
being significantly greater in the alclofenac-treated group (P=0-025).
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CLINICAL ASSESSMENT
During the study the change in each of the seven clinical indices by
which response was assessed was calculated for each patient for each
month, thus allowing us to place the patients into A.R.A. severity
classes A to J. We then analysed the changes in the patients' con-
ditions which occurred during the trial.
Preliminary analysis of the data showed that those with more severe
disease (initially grouped. into severity classes D-G) tended to
respond more favourably than those with less severe disease (classes
A-C). This phenomenon might be expected since the clinical measures
used allowed a greater potential for improvement in the more severely
affected patients. Indeed, the initial value of a clinical index had a
discernible effect on its change, and this was therefore corrected to
discriminate between changes due to treatment and those dependant
upon the initial severity class. The results were expressed as percentage
changes and then plotted graphically against initial severity classes
on the axis. Any trend dependent on initial severity scores was
eliminated by weighting the percentage improvements by amounts
related to the initial severity class. This weighting was achieved by
varying linear multiples of the class abscissal values and testing for
trend using the non-parametric Page's L-test (Page, 1963). Differences
between the treatments were then analysed by using the Mann-
Whitney U test.
Alclofenac produced a greater improvement than indomethacin
in both the duration of morning stiffness and the articular index
scores from the third month to the end ofthe study (table II). Improve-
ment in functional capacity was significantly greater in the alclofenac-
treated group at six months (table III), and this difference was main-
tained throughout the rest of the trial. No significant differences were
found at any time in grip-strength, digital joint size, or walking time.
TABLE II-Morning Stiffness and Articular Index Score at Three Months in
Two Groups of Patients with Rheumatoid Arthritis
Morning Stiffness (min) I
Treatment Mean Initial
Score
(± S.E.)
Articular Index
Mean Mean Initial Mean %
Reduction Score Reduction
at 3 Months (± S.E.) at 3 Months
Indomethacin. . 224 6-1 348 507 ± 3.8 126
Alclofenac . . 232 5-0 68-4* 53-1 ± 36 30-2t
*Alclofenac was better than indomethacin P <0-01 (Mann-Whitney U test).
tAlclofenac was better than indomethacin P<0 05 (Mann-Whitney U test).
TABLE iII-Functional Capacity at Six Months and 13 Months in Two Groups
of Patients with Rheumatoid Arthritis
Mean Initial Mean % Reduction of Initial Score
Treatment Score(± S.E.) at 6 Months at 13 Months
Indomethacin .. 1-9 + 0.11 9 0 15-1
Alclofenac .. .. 19 0-12 17-6* 492t
*Alclofenac better than indomethacin P <005 (Mann-Whitney U test).
tAlclofenac better than indomethacin P<0-002 (Mann-Whitney U test).
Classification of patients into A.R.A. severity classes on the basis
of weighted percentage improvements during each three-month period
of the trial indicated that the improvement noted with alclofenac was
reflected in patients graduating from more severe to less severe
classes. A similar phenomenon was not observed in the group receiving
indomethacin.
LABORATORY INVESTIGATIONS
Erythrocyte Sedimentation Rate.-In the indomethacin-treated patients
there was a median fall of 30% in the E.S.R. measurements while in
11 patients there was a mean increase of 38% (S.D. = 35%). This did
not represent a statistically significant change (Wilcoxon signed
ranks test: P>01). Alclofenac treatment produced a median fall
of 58% in E.S.R. during 13 months-a statistically significant reduc-
tion (Wilcoxon signed ranks test: P=001).
Haematology.-Throughout the study there were no consistent
changes in white cell and platelet counts in either treatment group.
Haemoglobin concentration remained unchanged in patients receiving
indomethacin, but after five months it had risen in the alclofenac
group, and this improvement was maintained. Altogether 22-5% of
I I~~~~~~~~~~~~~~
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the alclofenac group as against 5.0% of the indomethacin group
increased their haemoglobin concentration by 3 g/dl or more.
Rheumatoid Factor Tests.-Analysis, by a ranking procedure, of
the changes in latex-agglutination titres over 13 months in each
treatment group indicated that there was a statistically significant
fall in titres in the alclofenac group (Wilcoxon signed ranks test;
n= 19; T= 38; P= 0O01) which did not occur in patients treated with
indomethacin (n=8; T=18; P>0 10). There were no significant
changes in sheep-cell agglutination titres in either group, however.
STEROID REQUIREMENTS
Steroid requirements tended to fall in both treatment groups during
the first nine months of the study, but in the last three months there
was a mean increase in the steroid consumption in patients receiving
indomethacin. Because of the small numbers the differences between
the groups were never significant (P>010) (table IV).
TABLE Iv-Change in Prednisolone Intake in Two Groups of Patients with
Rheumatoid Arthritis. Numbers of Patients are given in Parentheses
Mean Initial Mean Reduction in Dose (mg) at:
Treatment Dose
( S.E.) (mg) 9 Months 13 Months
Alclofenac .. .. 8-2 (7) 1-6 (6) 2-3 (6)
Indomethacin .. .. 7-5 (8) 0 5 (7) Increase of:
0-5 (7)
WITHDRAWALS
Toxicity.-There were no instances of bone-marrow suppression,
apparent (biochemical) liver disturbance, raised blood urea, serious
infection, or death during the 13 months. Though there were fewer
withdrawals due to adverse effects among the alclofenac group than
among the indomethacin group (table V) the difference was not
significant. Most withdrawals were due to gastrointestinal disturbance,
which had a significantly greater incidence among those receiving
indomethacin.
Lack of Analgesia.-Nine patients (five on indomethacin, four on
alclofenac) were withdrawn from the study because of lack of analgesia
and significant increase in duration of morning stiffness. Eight were
withdrawn during the first six weeks of the trial, and the remaining
patient was withdrawn after four months of indomethacin treatment.
TABLE v-Incidence of Adverse Effects leading to Withdrawal in Both Treat-
ment Groups. Results are Numbers of Patients
Indomethacin Alclofenac
Gastrointestinal disturbance 5 2
Mental confusion, nausea, and vertigo (symptom
complex) 2 0
Gastric ulcer .1 0
Skin rash 1 4
Generalized pruritus .0 1
Severe sleep disturbance .2 0
Proteinuria . 1 0
Severe headache.1 0
Total .. 13 (22-4%) 7 (13-7%)
Discussion
Evaluation of the effects of any drug treatment in patients with
rheumatoid arthritis not only demands a controlled quantitative
approach, incorporating valid measures of clinical response, but
also must make allowances for the known spontaneous fluctua-
tions in disease activity. These factors are particularly relevant
to the interpretation of our data. Though ethical considerations
prevented the inclusion of an "untreated" control group the
clinical criteria and laboratory measures used were probably
sensitive enough for assessing change in patients' conditions.
The results clearly showed the efficacy of indomethacin and
alclofenac in the extended treatment of rheumatoid arthritis,
though important therapeutic differences did emerge. The
alclofenac group showed a significantly greater reduction in
the duration of morning stiffness and in the articular index
between three and 13 months, and functional capacity improved
significantly only in those receiving alclofenac. Both treatment
groups showed some evidence of a cortico steroid-sparing
effect during the first nine months of the study, but the small
numbers involved did not allow the demonstration of a statistical
significance. Only in the alclofenac group was it possible to
show a statistically significant reduction in E.S.R.
In 48% of patients the duration of disease activity was less
than three years, and it was less than five years in 62%. If our
results represent what can be achieved with relatively safe
non-steroidal drugs such as indomethacin and alclofenac in the
treatment of relatively early cases then the exposure of such
patients to the hazards of therapy with the antiproliferative
"immunosuppressive" drugs such as cyclophosphamide, aza-
thioprine, and chlorambucil seems unjustifiable, particularly
considering recent reports of their adverse effects on gonadal
function (Fairley et al., 1972; Kumar et al., 1972).
It might be argued that our results show a spurious improve-
ment because of the withdrawal of the most severely ill patients
or the admission of those with mild disease activity and sub-
jective improvement regardless of treatment. Analysis of the
admission criteria of patients withdrawn indicated, however,
that they had lesser disease activity, and rigid admission criteria
ensured that the patients had active disease. Assessment of
improvement based on several objective indices of response
over 13 months made it most improbable that subjective im-
provement regardless of treatment had any effect on the results.
Our results are not at variance with conclusions reached in
other more comprehensive and long-term studies of patients
with rheumatoid arthritis (Duthie et al., 1955, 1957, 1964),
which indicate that this disease is relatively benign. Most
patients are satisfactorily managed with simple, safe drugs
combined with measures to improve the patient's general
health and wellbeing (Duthie, 1971) and relatively few patients
with early disease will deteriorate much (Jacoby et al., 1973).
Most patients in the trial either improved or remained as
well controlled as on entry, irrespective of which drug they
received. Nevertheless, alclofenac proved the more effective
drug in producing clinical, haematological, and serological
evidence of improvement.
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